サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609690

日本の分子診断市場レポート：製品、技術、用途、エンドユーザー、地域別、2025年～2033年

Japan Molecular Diagnostics Market Report by Product, Technology (Polymerase Chain Reactions, Hybridization, DNA Sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology, and Others), Application, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 116 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
日本の分子診断市場レポート：製品、技術、用途、エンドユーザー、地域別、2025年～2033年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 116 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本の分子診断市場の市場規模は2024年に12億米ドルに達しました。今後、IMARC Groupは、2033年には21億米ドルに達し、2025年から2033年にかけて6%の成長率（CAGR）を示すと予測しています。がんや心血管疾患などの慢性疾患の有病率の増加、独自のヘルスケアニーズや特定疾患の高い傾向を必要とする老年人口の増加、次世代シーケンシングやリアルタイムPCRなどの先端技術の統合は、市場を牽引する主な要因のいくつかです。

本レポートで扱う主な質問

  • 日本の分子診断市場はこれまでどのような業績を上げてきたか、また今後数年間はどのような業績を上げるのか？
  • COVID-19の日本の分子診断市場への影響は？
  • 日本の分子診断市場の製品別構成比は？
  • 日本の分子診断市場の技術別構成比は？
  • 日本の分子診断市場の用途別内訳は？
  • 日本の分子診断市場のエンドユーザー別の内訳は？
  • 日本の分子診断市場のバリューチェーンにはどのような段階がありますか？
  • 日本の分子診断市場の主な促進要因と課題は何か？
  • 日本の分子診断市場の構造と主要プレーヤーは？
  • 日本の分子診断市場の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本の分子診断市場：イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本の分子診断市場情勢

  • 過去および現在の市場動向（2019年～2024年）
  • 市場予測（2025-2033）

第6章 日本の分子診断市場：製品別内訳

  • 試薬とキット
  • 機器
  • ソフトウェアとサービス

第7章 日本の分子診断市場：技術別内訳

  • ポリメラーゼ連鎖反応（PCR）
  • 交配
  • DNA配列解析
  • マイクロアレイ
  • 等温核酸増幅技術（INAAT）
  • その他

第8章 日本の分子診断市場：用途別内訳

  • 感染症診断
  • 腫瘍学
  • 遺伝子検査
  • 血液検査
  • その他

第9章 日本の分子診断市場：エンドユーザー別内訳

  • 病院
  • ラボ
  • その他

第10章 日本の分子診断市場：競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第11章 主要企業のプロファイル

第12章 日本の分子診断市場：業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第13章 付録

目次
Product Code: SR112024A11068

The Japan molecular diagnostics market size reached USD 1.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.1 Billion by 2033, exhibiting a growth rate (CAGR) of 6% during 2025-2033. The increasing prevalence of chronic diseases, including cancer and cardiovascular ailments, the growing geriatric population requiring unique healthcare needs and a higher propensity for specific diseases, and the integration of advanced technologies such as next-generation sequencing and real-time PCR represent some of the key factors driving the market.

Molecular diagnostics refers to a collection of techniques used to analyze biological markers in the genome and proteome. This category of diagnostics enables medical professionals to detect and measure the presence of genetic material or proteins associated with a specific health condition or disease state. Molecular diagnostics are characterized by their precision, accuracy, and speed, as well as their essential role in the healthcare system. These diagnostic methods employ technologies such as PCR (polymerase chain reaction), ISH (in situ hybridization), and DNA sequencing to uncover specific genetic information. Their working mechanism involves extracting, amplifying, and analyzing genetic material, starting with the isolation of DNA or RNA to amplify targeted genetic regions. The amplified genetic material is then examined through various methods to identify mutations or changes, enabling healthcare providers to make informed decisions about diagnosis and treatment. The properties of molecular diagnostics such as sensitivity, specificity, and the ability to process multiple samples simultaneously make them advantageous in providing timely and tailored medical treatments, thereby offering a promising system to personalized medicine.

Japan Molecular Diagnostics Market Trends:

The market in Japan is primarily driven by the increasing prevalence of chronic diseases, including cancer and cardiovascular ailments, which necessitates the need for early and precise detection. In line with this, the growing geriatric population in Japan, requiring unique healthcare needs and a higher propensity for specific diseases, is also providing an impetus to the market. Moreover, the integration of advanced technologies such as next-generation sequencing and real-time PCR is acting as a significant growth-inducing factor for the market. In addition to this, the consistent support from the Japanese government in terms of funding and favorable regulatory guidelines is resulting in a more conducive environment for research and development. Besides this, the growing awareness about personalized medicine, coupled with a strong emphasis on research collaboration between academic institutions and private enterprises, is creating lucrative opportunities in the market. Also, the wide availability of molecular diagnostic platforms across various healthcare settings is impacting the market positively. The market is further driven by the robust investment in healthcare infrastructure and the strategic alignment of public health goals with technological innovation. Apart from this, the penetration of health insurance, focusing on preventive care and early diagnosis, along with the proliferation of specialized laboratories and clinics, is propelling the market. Some of the other factors contributing to the market include Japan's highly educated workforce, sophisticated healthcare system, and a cultural emphasis on precision and innovation in medical science and technology.

Japan Molecular Diagnostics Market Segmentation:

Product Insights:

  • Reagents and Kits
  • Instruments
  • Software and Services

Technology Insights:

  • Polymerase Chain Reactions (PCR)
  • Hybridization
  • DNA Sequencing
  • Microarray
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Others

Application Insights:

  • Infectious Diseases Diagnostics
  • Oncology
  • Genetic Testing
  • Blood Screening
  • Others

End User Insights:

  • Hospitals
  • Laboratories
  • Others

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan molecular diagnostics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan molecular diagnostics market?
  • What is the breakup of the Japan molecular diagnostics market on the basis of product?
  • What is the breakup of the Japan molecular diagnostics market on the basis of technology?
  • What is the breakup of the Japan molecular diagnostics market on the basis of application?
  • What is the breakup of the Japan molecular diagnostics market on the basis of end user?
  • What are the various stages in the value chain of the Japan molecular diagnostics market?
  • What are the key driving factors and challenges in the Japan molecular diagnostics market?
  • What is the structure of the Japan molecular diagnostics market and who are the key players?
  • What is the degree of competition in the Japan molecular diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Molecular Diagnostics Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Molecular Diagnostics Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Molecular Diagnostics Market - Breakup by Product

  • 6.1 Reagents and Kits
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Instruments
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Software and Services
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)

7 Japan Molecular Diagnostics Market - Breakup by Technology

  • 7.1 Polymerase Chain Reactions (PCR)
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Hybridization
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 DNA Sequencing
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)
  • 7.4 Microarray
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2019-2024)
    • 7.4.3 Market Forecast (2025-2033)
  • 7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2019-2024)
    • 7.5.3 Market Forecast (2025-2033)
  • 7.6 Others
    • 7.6.1 Historical and Current Market Trends (2019-2024)
    • 7.6.2 Market Forecast (2025-2033)

8 Japan Molecular Diagnostics Market - Breakup by Application

  • 8.1 Infectious Diseases Diagnostics
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Oncology
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Genetic Testing
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)
  • 8.4 Blood Screening
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2019-2024)
    • 8.4.3 Market Forecast (2025-2033)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2019-2024)
    • 8.5.2 Market Forecast (2025-2033)

9 Japan Molecular Diagnostics Market - Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2019-2024)
    • 9.1.3 Market Forecast (2025-2033)
  • 9.2 Laboratories
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2019-2024)
    • 9.2.3 Market Forecast (2025-2033)
  • 9.3 Others
    • 9.3.1 Historical and Current Market Trends (2019-2024)
    • 9.3.2 Market Forecast (2025-2033)

10 Japan Molecular Diagnostics Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Molecular Diagnostics Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix